Inclusion Criteria:

1. The patient must have histologically-confirmed, unresectable HCC.
2. The patient has at least one unidimensionally-measurable target lesion (≥ 2 cm with conventional techniques, or ≥ 1 cm by spiral CT or MRI), as defined by Response Evaluation Criteria in Solid Tumors (RECIST).[61] Target lesion(s) must not lay within a previously irradiated, ablated, or chemoembolized area. If a target lesion does lie in such an area, there must be evidence of growth on successive imaging studies, including tumor hypervascularity, in order for such a lesion to be considered a target lesion.
3. The patient is age ≥ 18 years.
4. The patient has a life expectancy of ≥ 12 weeks.
5. The patient has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1 at study entry.
6. The patient has a Cancer of the Liver Italian Programme (CLIP) score of 0-3 (see Section 3.2.1).
7. The patient has a Child-Pugh Classification score of A or B (liver dysfunction, see Section 3.2.1).
8. The patient has adequate hepatic function as defined by a total bilirubin ≤ 3.0 mg/dL, and aspartate transaminase (AST) and alanine transaminase ALT)≤ 5 times upper limit of normal (ULN).
9. The patient has adequate renal function as defined by serum creatinine ≤ 2.0 mg/dL.
10. The patient's urinary protein is ≤ 1+ on dipstick or routine urinalysis (UA). If urine dipstick or routine analysis indicated ≥ 2+ proteinuria, then a 24-hour urine must be collected and must demonstrate < 1000 mg of protein in 24 hours to allow participation in the study.
11. The patient has adequate hematologic function, as evidenced by an absolute neutrophil count (ANC) ≥ 1.0 x 109/L, hemoglobin ≥ 10 g/dL, and platelets ≥ 75 x 109/L.
12. The patient must have adequate coagulation function as defined by International Normalized Ratio (INR) ≤ 1.5 and a partial thromboplastin time (PTT)≤ 5 seconds above ULN.
13. The patient agrees to use adequate contraception during the study period and for 4 weeks after the last dose of study treatment. Patients must notify the principal investigator if they themselves or their partner becomes pregnant.
14. The patient has resolution to Grade ≤ 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3 (NCI-CTCAE v 3.0) of all clinically significant toxic effects of prior locoregional therapy, surgery,chemoembolization, or other anticancer therapy.
15. The patient has provided signed informed consent.

Exclusion Criteria:

1. The patient has received prior systemic chemotherapy, biologic or anti-angiogenic therapy, or investigational systemic therapy for HCC.
2. The patient has undergone surgery within 28 days of study entry excluding prior diagnostic biopsy or venous access device placement.
3. The patient has received chemoembolization, irradiation, or other locoregional therapy for HCC within 28 days of study entry.
4. The patient has gastric varices that are not amenable to ablative therapy.
5. The patient has ascites or encephalopathy refractory to medical management.
6. The patient has had bleeding from esophageal or gastric varices during the 3 months prior to study participation. Note: If the patient has any history of known esophageal varices, or evidence of esophageal varices on CT/MRI, the patient must undergo endoscopic evaluation prior to study entry (minimally invasive capsule esophageal endoscopy is an acceptable initial modality). The patient with endoscopically detected esophageal varices is eligible provided he/she meets all other entry criteria. The patient with any history or current evidence of esophageal varices must receive oral beta-blocker therapy throughout participation while on study, he/she may receive optimal endoscopic therapy as determined by the consulting gastroenterologist or hepatologist, and must undergo regular endoscopic follow-up throughout participation while on study.
7. The patient has acute hepatitis.
8. The patient has fibrolamellar HCC.
9. The patient has central nervous system (CNS) metastases or carcinomatous meningitis.
10. The patient has an ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorders in the opinion of the investigator.
11. The patient has poorly-controlled hypertension (ie, blood pressure in abnormal range despite medical management).
12. The patient has received previous therapy with any agent that targets VEGF or VEGFR-2 (including multi-targeted tyrosine kinase inhibitors).
13. The patient has a known allergy to any of the treatment components.
14. The patient, if female, is pregnant (confirmed by urine or serum beta human chorionic gonadotropin [βHCG] test) or breast-feeding.
15. The patient is HIV-positive.